Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yuxiao Hu
Observed names:
Y Hu,
Y. Hu
Institutions:
Jiangsu Cancer Hospital,
Nanjing Medical University
Observed institutions:
Central South University,
First Affiliated Hospital of Xinjiang Medical University,
Hunan Cancer Hospital,
Jiangsu Cancer Hospital,
Nanjing Medical University
ORCID:
0000-0003-3520-6634
Observed ORCID:
0000-0003-3520-6634
OpenAlex ID:
A5102750652
Correlation of quantitative parameters of magnetic resonance perfusion‐weighted imaging with vascular endothelial growth factor, microvessel density and hypoxia‐inducible factor‐1α in nasopharyngeal carcinoma: Evaluation on radiosensitivity study
2017
·
Y. Hu
, H. E
, et al.
·
Clinical Otolaryngology
·
14
Development and Validation of an 18F-FDG PET/CT-based Radiomics Nomogram for Predicting the Prognosis of Patients with Esophageal Squamous Cell Carcinoma
2024
·
Jiahui Huang
, Tiannv Li
, et al.
·
Academic Radiology
·
4
[The effect of tumor spread through air spaces on the prognosis of patients with stage Ⅰ non-small cell lung cancer: a meta-analysis].
2023
·
Abla Nurmamat
, Y Hu
, et al.
·
PubMed
·
3
Integrated primary tumor and all metastatic lymph nodes radiomics from 18 F-FDG PET/CT for precise M1 subclassification in nasopharyngeal carcinoma
2026
·
Yun Zhang
, Shanshan Xu
, et al.
·
BMC Cancer
·
1
Validation of the 2018 FIGO staging system for stage IIIC cervical cancer by determining the metabolic and radiomic heterogeneity of primary tumors based on 18F-FDG PET/CT
2024
·
Yun Zhang
, Yuxiao Hu
, et al.
·
Abdominal Radiology
·
1
Lymph node metastasis of T1, T2 squamous carcinoma and adenocarcinoma of lung: characteristics and clinical significance.
2000
·
Y Li
, H Liu
, et al.
·
PubMed
·
1
IMPI refines prognostic stratification among non-high NCCN-IPI risk DLBCL patients treated with R-CHOP: a real-world cohort study
2026
·
Silu Cui
, Qi Jiang
, et al.
·
BMC Cancer
Metabolic Tumor Area: A Clinically Practical Prognostic Marker for Improved Risk Stratification in IPI Non‐High‐Risk DLBCL
2026
·
Silu Cui
, Qi Jiang
, et al.
·
Hematological Oncology
18F-FDG PET/CT radiomics combined with double-expressor status enhances prognostication and high-risk stratification in DLBCL
2026
·
Qi Jiang
, Silu Cui
, et al.
·
BMC Medical Imaging
Metabolic Bulk Volume is an independent prognostic factor and facilitates identifying high risk cases for DLBCL patients treated with the R-CHOP
2026
·
Silu Cui
, Panpan Luan
, et al.
·
Frontiers in Oncology
PDF
Show more works
View as search
Works count:
10
Citation count:
24
H-index:
3
I10-index:
1
Year
Topic
Type